Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical, imaging, serological, and histopathological features of pulmonary post-acute sequelae after mild COVID-19 (PASC)

D Gagiannis, C Hackenbroch, A Czech, A Lindner, N Maag, W Bloch, F Zech, F Kirchhoff, S Djudjaj, S von Stillfried, R Bülow, View ORCID ProfileP Boor, View ORCID ProfileK Steinestel
doi: https://doi.org/10.1101/2022.11.29.22282913
D Gagiannis
1Department of Pulmonology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Hackenbroch
2Department of Radiology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany
3Department of Radiology, Ulm University Medical Center, 89081 Ulm, Albert-Einstein-Allee 23, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Czech
4Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Lindner
1Department of Pulmonology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N Maag
4Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W Bloch
5Department of Molecular and Cellular Sport Medicine, German Sport University Cologne, 50933 Cologne, Am Sportpark Müngersdorf 6, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Zech
6Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Meyerhofstr. 1, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Kirchhoff
6Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Meyerhofstr. 1, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Djudjaj
7Institute of Pathology, RWTH Aachen University Hospital, 52074 Aachen, Pauwelsstrasse 30, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S von Stillfried
7Institute of Pathology, RWTH Aachen University Hospital, 52074 Aachen, Pauwelsstrasse 30, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Bülow
7Institute of Pathology, RWTH Aachen University Hospital, 52074 Aachen, Pauwelsstrasse 30, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Boor
7Institute of Pathology, RWTH Aachen University Hospital, 52074 Aachen, Pauwelsstrasse 30, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P Boor
K Steinestel
4Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for K Steinestel
  • For correspondence: konradsteinestel@bundeswehr.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background A significant proportion of patients experience prolonged pulmonary, cardiocirculatory or neuropsychiatric symptoms after Coronavirus disease 2019 (COVID-19), termed post-acute sequelae of COVID (PASC). Lung manifestations of PASC include cough, dyspnea on exertion and persistent radiologic abnormalities and have been linked to viral persistence, ongoing inflammation and immune dysregulation. So far, there is limited data on lung histopathology and tissue-based immune cell subtyping in PASC.

Methods 51 unvaccinated patients (median age, 40 years; 43% female) with a median of 17 weeks (range, 2-55 weeks) after mild SARS-CoV-2 infection (without hospitalization) underwent full clinical evaluation including high-resolution computed tomography (HR-CT) and transbronchial biopsy. We used RT-PCR/FISH and immunohistochemistry (nucleocapsid/spike/CD3/CD4/CD8) for residual SARS-CoV-2 detection and T lymphocyte subtyping, respectively. We assessed interstitial fibrosis and macrophage profiles by transmission electron microscopy (TEM) and immunofluorescence multiplex staining, while cytokine profiling in bronchoalveolar lavage (BAL) fluid was performed by legendplex immunoassay.

Results Dyspnea on exertion was the leading symptom of pulmonary PASC in our cohort. In 16% and 42.9% of patients, FEV1 and MEF50 were ≤ 80% and 35.3% showed low attenuation volume (LAV) in >5% of lung area, in line with airflow obstruction. There was a significant correlation between oxygen pulse and time since COVID (p=0.009). Histopathologically, PASC manifested as organizing pneumonia (OP), fibrinous alveolitis and increased CD4+ T cell infiltrate predominantly around airways (bronchiolitis), while the residual virus components were detectable in only a single PASC patient (2%). T cell infiltrates around small airways were inversely correlated with time since COVID, however, this trend failed to reach statistical significance. We identified discrete interstitial fibrosis and a pro-fibrotic macrophage subtype (CD68/CD163/S100A9) as well as significantly elevated interleukin 1β in BAL fluid from PASC patients (p=0.01), but H-scores for fibrotic macrophage population did not correlate with severity of clinical symptoms or T cell infiltration.

Interpretation We show decreased FEV1/MEF50 and increased LAV in line with obstructive lung disease due to CD4+ T cell-predominant bronchiolitis as well as evidence of pro-fibrotic signaling in a subset of unvaccinated PASC patients. Since our results point towards self-limiting inflammation of small airways without detectable viral reservoirs, it remains unclear whether pulmonary symptoms in PASC are SARS-CoV-2-specific or represent a general response to viral infection. Still, evidence of pro-fibrotic signaling should warrant clincal follow-up and further research into possible long-time fibrotic remodeling in PASC patients.

Key points

  • Dyspnea on exertion is the leading clinical manifestation of PASC in the lung

  • a minority of pts have significantly impaired lung function (FVC/TLC≤80% or DLCO≤70%) in spiroergometry and/or radiologic abnormalities, oxygen pulse seems to normalize over time

    • 16% and 42.9% of pts have FEV1 and MEF50≤80% and 35.3% have LAV>5% of lung area, in line with airflow obstruction due to bronchiolitis

  • Residual virus was not detectable in the lung tissue of all but one PASC patient (2%)

  • Histologically, PASC may manifest as T cell-mediated bronchiolitis, OP and fibrinous alveolitis

  • There is evidence of fibrotic remodeling (ultrastructural interstitial fibrosis, pro-fibrotic macrophage subpopulation, pro-fibrotic cytokine IL-1β in BAL) but this did not correlate with the degree of T cell infiltrate/bronchiolitis

Competing Interest Statement

DG and KS were speakers for Boehringer-Ingelheim. All other authors declare no conflict of interest.

Funding Statement

This work was in part supported by the German Registry of COVID-19 Autopsies (www.DeRegCOVID.ukaachen.de), funded by the Federal Ministry of Health (ZMVI1-2520COR201), and the Federal Ministry of Education and Research within the framework of the network of university medicine (NATON, No. 01KX2121). FZ and FK are supported by CRC 1279.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethics committee of the University of Ulm gave ethical approval for this work (ref. no. 129-20) .

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This work was in part supported by the German Registry of COVID-19 Autopsies (www.DeRegCOVID.ukaachen.de), funded by the Federal Ministry of Health (ZMVI1-2520COR201), and the Federal Ministry of Education and Research within the framework of the network of university medicine (NATON, No. 01KX2121). FZ and FK are supported by CRC 1279.

  • Declaration of interest: DG and KS were speakers for Boehringer-Ingelheim. All other authors declare no conflict of interest.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 30, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical, imaging, serological, and histopathological features of pulmonary post-acute sequelae after mild COVID-19 (PASC)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical, imaging, serological, and histopathological features of pulmonary post-acute sequelae after mild COVID-19 (PASC)
D Gagiannis, C Hackenbroch, A Czech, A Lindner, N Maag, W Bloch, F Zech, F Kirchhoff, S Djudjaj, S von Stillfried, R Bülow, P Boor, K Steinestel
medRxiv 2022.11.29.22282913; doi: https://doi.org/10.1101/2022.11.29.22282913
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Clinical, imaging, serological, and histopathological features of pulmonary post-acute sequelae after mild COVID-19 (PASC)
D Gagiannis, C Hackenbroch, A Czech, A Lindner, N Maag, W Bloch, F Zech, F Kirchhoff, S Djudjaj, S von Stillfried, R Bülow, P Boor, K Steinestel
medRxiv 2022.11.29.22282913; doi: https://doi.org/10.1101/2022.11.29.22282913

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (502)
  • Anesthesia (110)
  • Cardiovascular Medicine (1234)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (530)
  • Epidemiology (10015)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2449)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1638)
  • Health Policy (751)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (532)
  • Infectious Diseases (except HIV/AIDS) (11862)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2278)
  • Nursing (139)
  • Nutrition (350)
  • Obstetrics and Gynecology (453)
  • Occupational and Environmental Health (535)
  • Oncology (1245)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (155)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4829)
  • Radiology and Imaging (834)
  • Rehabilitation Medicine and Physical Therapy (490)
  • Respiratory Medicine (651)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (226)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)